selpercatinib

Roche's FoundationOne CDx cancer genomic profiling test was approved for the RET receptor tyrosine kinase inhibitor for RET fusion-positive solid tumors. 

Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.

The collaboration will initially explore the use of FoundationOne CDx for patients with metastatic rearranged transfection fusion across tumor types.